Am J Manag Care by Schmittdiel, Julie A. et al.
The Safety and Effectiveness of Mail Order Pharmacy Use in 
Diabetes Patients
Julie A. Schmittdiel, PhD1, Andrew J. Karter, PhD1, Wendy Dyer, MS1, James Chan, 
PharmD, PhD2, and O. Kenrik Duru, MD, MSHS3
1Division of Research, Kaiser Permanente Northern California, Oakland, CA
2Pharmacy Outcomes Research Group, Kaiser Permanente Northern California, Oakland, CA
3David Geffen School of Medicine; University of California, Los Angeles; Los Angeles, CA
Abstract
Background—Research suggests mail order pharmacy use is associated with greater medication 
adherence and CVD risk factor control. However, no research has examined the potential impact 
of mail order pharmacy use on patient safety and utilization.
Objective—To compare safety and utilization outcomes in patients using mail order vs. local 
pharmacies.
Subjects—17,217 Kaiser Permanente Northern California (KPNC) adult diabetes patients 
prescribed new cardiometabolic medications in 2006.
Research Design—Cross-sectional, observational study.
Measures—Outcomes included any all-cause and preventable hospitalizations and emergency 
department (ED) visits; laboratory tests for monitoring persistent medications; and overlapping 
days’ supply of contraindicated medications. Multivariate logistic regression results were stratified 
by patient age and converted to adjusted predicted percentages.
Results—Overall, there were few differences in outcomes between mail order and local 
pharmacy users. Patients < 65 using mail order had fewer ED visits (34.0% vs. 40.2%; p<.001); 
preventable ED visits (7.8% vs. 9.6%; p<.01); and serum creatinine laboratory monitoring tests 
after ACE/ARB or diuretic initiation (41.4% vs. 47.2%; p<.01). Among patients ≥65, mail order 
users had fewer preventable ED visits (13.4% vs. 16.3%; p<.01); but more occurrences of 
overlapping days’ supply of contraindicated medications (1.1% vs. 0.7%; p<.01).
Conclusions—Mail order pharmacy use is not associated with adverse outcomes in most 
diabetes patients, and is associated with lower ED use. Interventions to increase mail order 
pharmacy use may be an important strategy for improving care; however, these interventions 
should employ a patient-centered approach that is sensitive to primary and preventive care access.
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Mail order pharmacies are widely used to deliver medications in the U.S., with up to 1/3 of 
chronic illness medications delivered by mail.1–2 Research suggests a positive association 
between mail order pharmacy use and greater adherence to diabetes and antihypertensive 
medications, 3–6 and with better LDL-C control.7 These favorable outcomes may reflect 
improved access to medications with mail order pharmacy use,8 which may be of particular 
value to patients with disabilities, time constraints, or limited transportation (Figure 1).3,8 
However, there may be unintended consequences to using mail order pharmacies. When 
medical offices and pharmacies are in the same location, patients who use mail-order 
pharmacies may be less likely to access preventive care services. This may increase the risk 
of hospitalizations and emergency department (ED) visits that are sensitive to preventive 
care quality.9,10 Diabetes patients, who often take multiple medications, may be particularly 
at-risk for exposure to contraindicated medications;11–12 mail order pharmacy users may 
miss face-to-face consultations with pharmacists and physicians designed to prevent 
contraindicated medication use. Finally, many medications require laboratory monitoring to 
reduce the risk of potential adverse drug events:13 mail order pharmacy use may 
inadvertently reduce the likelihood such tests are ordered by physicians and completed by 
patients. The purpose of this study is to examine the relationship of mail order pharmacy use 
with safety and healthcare outcomes in diabetes patients, and whether effects vary by key 
patient characteristics.
Methods
Study Population and Setting
This study was conducted within Kaiser Permanente Northern California (KPNC), an 
integrated health system providing comprehensive medical care to over three million 
members. Patients were included in the study if they had diabetes, were ≥18 years of age by 
January 1, 2006, and had been prescribed a new (no use in the past 24 months) antiglycemic, 
antihypertensive, or lipid-lowering medication from January 1 – May 31, 2006. If patients 
were prescribed multiple new cardiometabolic medications during this period, the earliest 
prescription was defined as the “index medication.” We excluded the small proportion 
(<5%) of members who lacked KPNC drug benefits during the study period.
KPNC maintains a mail order pharmacy distribution system in coordination with over 120 
local “walk-in” KPNC pharmacies located within outpatient clinics and hospitals.3,7 The 
first fill of a medication is typically at a local KPNC pharmacy, and includes a pharmacist 
consultation. Patients may then refill existing prescriptions either by mail or at any KPNC 
local pharmacy. Mail delivery of medications, with free shipping, can be requested by phone 
or online. While KPNC members also have the option of filling prescriptions at non-KPNC 
pharmacies, the cost of these fills are not covered by the patient’s pharmacy benefit. 
Pharmacists are available via telephone to answer medication-related questions regardless of 
the mode of delivery. There is no proscribed days’ supply of pills required for mail delivery; 
KPNC typically dispenses 100-day supplies through both mail order and local pharmacies. 
Some patients have a financial incentive to use mail order in the form of a lower co-payment 
for the same days’ supply. For this analysis, patients were defined as local KPNC pharmacy 
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users if they never used the mail order pharmacy to fill the new index medication in the 12 
months post-initiation, and as a mail-order pharmacy user if they filled the index medication 
at least once via mail during that timeframe.
Outcome Variables
All-cause hospitalizations, preventable hospitalizations, all-cause ED use, and preventable 
ED use were defined as zero vs. one or more episodes in the 3 years post-index medication 
initiation date. Hospitalizations and ED visits were defined as ‘preventable’ using validated 
lists geared towards sensitivity to primary care access.9,10,14
Among patients whose index medication was an angiotensin-converting enzyme (ACE) 
inhibitor, angiotensin receptor blocker (ARB), or diuretic, we examined whether there was 
an appropriate potassium or serum creatinine lab test within 30 days post-index date.13,15 
These tests monitor for the possibility of electrolyte abnormalities or decreased renal 
function in patients new to these medications.
Potential for serious medication interaction was defined using a published list of 
contraindicated medications,16 and operationalized as two or more occurrences of 
overlapping days’ supply of contraindicated drugs (e.g., anti-coagulants and thyroid 
hormones) for one or more days in the 15 months post-index date.
Statistical Analysis
We estimated separate logistic regression models to examine the relationship between mail 
order pharmacy use and each outcome variable. In each analysis, we adjusted for age; sex; 
race/ethnicity; neighborhood deprivation score calculated with geocoded census 
socioeconomic data; 17–18 number of comorbidities; smoking status; use of non-formulary 
medications, antidepressants, or insulin; whether the index medication was generic or brand 
name; length of therapy with the index medication, days’ supply of the first refill; and 
medical facility. Detailed definitions of these variables has been published previously.3 
Patients with missing covariates (n=85) were excluded from the analysis. Models included 
interaction terms for mail order use with age, race/ethnicity, and deprivation score to assess 
whether different groups of patients might be more vulnerable to potential safety concerns 
with using the mail order pharmacy. Since the age interaction was the only interaction term 
that was significant, we present the results as adjusted percentages from models stratified by 
age <65 vs. age 65 plus.
Omitted (unmeasured) variable bias, or self-selection, may be of particular concern when 
studying the impact of mail order pharmacy use on outcomes; it is possible that patients who 
use the mail order pharmacy are different from those who do not in ways we are unable to 
measure (e.g., patient motivation). We employed health econometric techniques, specifically 
a bivariate probit (BVP) model incorporating an instrumental variable, to assess whether our 
estimates from the logistic regression predicting safety outcomes may be subject to such 
bias.19 We used distance from the patient’s home to their nearest local KPNC pharmacy as 
our instrumental variable, based on both empirical and theoretical considerations.3,20–21 An 
instrumental variable is required to be related directly to exposure (in this case, mail order 
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pharmacy use), but not directly to the outcomes of interest.22 We found greater distance to a 
local pharmacy was associated with mail-order pharmacy use in unadjusted analyses 
(X2=78.48, p<0.001), but was not independently associated with our outcomes. The 
likelihood-ratio test for endogeneity in the BVP models were all non-significant (p-values 
0.08–0.93, data not shown), suggesting no evidence of omitted variable bias; therefore we 
report results from the more efficient logistic regression analyses.
All analyses were performed using Stata Version 10.1. The study protocol was approved by 
the KPNC Institutional Review Board.
Results
A total of 17,217 diabetes patients met study eligibility criteria. Of these, 5,890 (34.1%) 
used the mail order pharmacy at least once to refill their new cardiometabolic medication 
during the study period (Table 1). Mail order pharmacy users were more likely to be white 
(56.7% vs. 37.1%, p<.001) and to live in census tracts with higher socioeconomic status (p<.
001).
Table 2 shows the adjusted predicted percentages of patients experiencing each outcome, 
stratified by age. After adjustment for demographic, clinical and census-block 
characteristics, patients < 65 using the mail order pharmacy were less likely to have an all-
cause ED visit (34.0% vs. 40.2%, p<.001); less likely to have a preventable ED visit (7.8% 
vs. 9.6%, p<.01); and less likely to receive a serum creatinine lab test within 30 days if their 
index medication was an ACE, ARB, or diuretic (41.4% vs. 47.2%; p<.01). Among patients 
≥ 65, those using mail order were less likely to experience a preventable ED visit (13.4% vs. 
16.3%; p<.05) and slightly more likely to experience two or more occurrences of overlap in 
days’ supply of contraindicated medications (1.1% vs. 0.7%; p<.01).
Discussion
This is the first study to examine the relationship between mail order pharmacy use and 
patient safety and utilization outcomes. We found that mail order use was not negatively 
associated with patient safety outcomes overall, suggesting mail order use does not serve as 
a barrier to receiving primary and preventive care services for most patients. Patients < 65 
using the mail order pharmacy did have slightly lower rates of serum creatinine testing with 
ACE, ARB, or diuretic use (41.4% v. 47.2%, p<.01). While there was no statistically 
significant difference in potassium laboratory testing in this group, or for any lab testing in 
patients ≥65, our findings suggest that in-person pharmacy refills may increase opportunities 
for monitoring of persistent medications in settings where laboratories and pharmacies are 
co-located.
Our study also found that patients ≥ 65 had slightly higher rates of two or more occurrences 
of overlapping days’ supply of contraindicated medications. While these rates were 
extremely low for both mail order and local pharmacy users (1.1% and 0.7%, respectively), 
our analysis adds to the evidence suggesting older patients using multiple medications may 
require additional monitoring for adverse events.12,13 It is important that pharmacies provide 
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increased access to chronic illness medications while also maintaining appropriate systems 
for preventing contraindicated medication use.
We found mail order pharmacy use was associated with lower overall ED use in patients 
<65, as well as lower preventable ED use in patients in all age groups. Previous studies have 
shown mail order use is associated with greater medication adherence 3–6 and LDL-C 
control.7 Since good medication adherence and CVD risk factor control are associated with 
reduced hospitalizations and better outcomes,23–25 mail order use may lead to lower 
preventable utilization over time.
Mail order pharmacy services, which are provided at the health care delivery system level 
rather than the physician or practice level, can be considered a structural or system-level 
intervention for improving access to chronic illness medications.3,7 While this study and 
others 3–7 suggest using mail order pharmacy services may improve outcomes, our study 
also suggests that certain patients may be more sensitive to any potential negative impact of 
mail order pharmacy use on health care access. System-level efforts to promote mail order 
use should preserve patient choice in pharmacy services and maintain a patient-centered 
approach to meeting an individual’s overall healthcare needs. Future research should 
continue to address the important issue of how to appropriately target and promote mail 
order pharmacy services while preserving the benefits of in-person interaction with 
pharmacists and other care providers.
This study has several limitations. Observational studies cannot entirely control for 
differences between patients who use mail order pharmacy services and those that do not. 
While we used instrumental variable analyses to test for the evidence of such biases, it is 
possible that were unable to completely control for these differences. Future research should 
leverage randomized controlled trial designs to examine the impact of mail order pharmacy 
use on intermediate outcomes, healthcare utilization, and patient safety.
We were unable to ascertain pharmacy utilization at non-KPNC pharmacies. However, we 
limited our analyses to members with a drug benefit, which is only recognized at KPNC 
pharmacies. This under-ascertainment should be minimal, as previous research suggests that 
diabetes patients with drug benefits report extremely low use of non-KPNC pharmacies.26
This study was conducted in an integrated delivery system where patients access 
prescription medications differently than in many other settings. Use of “brick and mortar” 
pharmacies to fill prescriptions is primarily limited to KPNC local pharmacies; KPNC’s 
mail order and local pharmacies do not differ in the standard days’ supply of pills issued; 
and mail order pharmacy does not require physician enrollment of the prescription. KPNC 
local pharmacies are primarily ‘co-located’ with medical offices and laboratories, which is 
often not the case in other settings. It is therefore possible that the use of mail order 
pharmacy services in KPNC has a different impact on outcomes than in other settings.
Conclusion
Mail order pharmacy use is not associated with adverse events in most diabetes patients, and 
may be associated with improved health outcomes. System-level interventions to increase 
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mail order pharmacy use may be an important strategy for improving processes and 
outcomes of care for patients with chronic illness; however, these interventions should 
employ a patient-centered approach that does not increase risk in older patients and others 
who may be sensitive to primary and preventive care access.
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Table 1
Patient Characteristics
Entire Sample (n=17,217) Mail-Order Pharmacy 
Users (n=5,890)
Local Pharmacy Users 
(n=11,327)
Female (%) 46.4 46.0 46.7
Mean age (in years) (SD) 62 (11.9) 63 (11.7) 62 (12.0)***
Race/ethnicity
 White, non-Latino (%) 43.8 56.7 37.1***
 African American, non-Latino (%) 9.1 4.7 11.4***
 Latino (%) 8.8 6.0 10.2***
 Asian (%) 10.9 9.5 11.6***
 Native American (%) 1.7 1.9 1.6
 Mixed-race (%) 11.0 9.2 12.0***
 Missing race (%) 14.7 11.9 16.1***
Socioeconomic deprivation
 1st quartile (least deprived) (%) 20.5 25.8 17.8***
 2nd quartile (%) 28.9 30.0 28.3*
 3rd quartile (%) 26.3 23.3 27.8***
 4th quartile (most deprived) (%) 17.9 12.0 21.0***
 SES Missing 6.5 9.0 5.2***
Mean number of comorbidities (SD) 0.81 (1.1) 0.83 (1.0) 0.80 (1.1)*
Smoker (%) 7.7 7.0 8.0*
History of medication for depression (%) 22.1 24.0 21.1***
History of insulin use (%) 19.1 17.8 19.8***
History of nonformulary medication use (%) 6.0 6.4 5.8
New medication is brand-name (%) 22.3 24.0 21.4***
Medication days’ supply
 1–30 Days (%) 5.2 5.0 5.3
 31–60 Days (%) 5.4 5.5 5.4
 61–90 Days (%) 5.7 6.1 5.4
 >90 Days (%) 83.7 83.3 83.9
Mean # of Days from 1st Fill to Last Fill (SD) 349 (100) 362 (87) 342(106)***
*
p<.05 difference between groups
**
p<.01 difference between groups
***
p<.001 difference between groups
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Table 2
Predicted Percentages of Patients Experiencing Safety And Utilization Outcomes†
AGE<65 (n=9,851) AGE>=65 (n=7,281)
Outcome Local Pharmacy Users Mail-order Pharmacy Users Local Pharmacy Users Mail-order Pharmacy Users
At Least 1 
Hospitalization – All 
Cause
12.2% 11.2% 23.0% 22.5%
At Least 1 
Hospitalization – 
Preventable†
1.9% 1.4% 4.3% 3.7%
At Least 1 ED Visit 
– All Cause 40.2%
*** 34.0%*** 52.3% 49.7%
At Least 1 ED Visit 
– Preventable† 9.6%




0.5% 0.4% 0.7%** 1.1%**
(n=2,553) (n=2,026)
Had Potassium Lab 
Test within 30 days 43.4% 39.7% 50.5% 55.0%
Had Serum 
Creatinine Lab Test 
within 30 days
47.2%** 41.4%** 52.6% 56.1%
†
Adjusted for age; sex; race/ethnicity; neighborhood deprivation score; number of comorbidities; smoking status; use of non-formulary 
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